Tumor immunology

Advances in Experimental Medicine and Biology

Volumn 593, Issue , 2007, Pages 147-156

  Mocellin, Simone ^a   Lise, Mario ^a   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; INTERLEUKIN 10; INTERLEUKIN 2;

CANCER IMMUNOTHERAPY; CELL SURVIVAL; CLINICAL TRIAL; DENDRITE; DNA MICROARRAY; DRUG TARGETING; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HUMAN; IMMUNE RESPONSE; MICROARRAY ANALYSIS; MICROENVIRONMENT; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR; TUMOR IMMUNOLOGY; TUMOR REJECTION;

EID: 84934434841     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-39978-2_14     Document Type: Review

References (51)

1. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2:227-38.
2. Mocellin S, Mandruzzato S, Bronte V et al. Part I: Vaccines for solid tumours. Lancet Oncol 2004; 5:681-9.
3. Mocellin S, Semenzato G, Mandruzzato S et al. Part II: Vaccines for haematological malignant disorders. Lancet Oncol 2004; 5:727-37.
4. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380-4.
5. Pinkel D, Segraves R, Sudar D et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998; 20:207-11.
6. Broude NE. Differential display in the time of microarrays. Expert Rev Mol Diagn 2002; 2:209-16.
7. Velculescu VE, Zhang L, Vogelstein B et al. Serial analysis of gene expression. Science 1995; 270:484-7.
8. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999; 21:33-7.
9. Goldenfeld N, Kadanoff LP. Simple lessons from complexity. Science 1999; 284:87-9.
10. Staudt LM, Brown PO. Genomic views of the immune system*. Annu Rev Immunol 2000; 18:829-59.
11. Ricciardi-Castagnoli P, Granucci F. Opinion: Interpretation of the complexity of innate immune responses by functional genomics. Nat Rev Immunol 2002; 2:881-9.
12. Keil D, Luebke RW, Pruett SB. Quantifying the relationship between multiple immunological parameters and host resistance: Probing the limits of reductionism. J Immunol 2001; 167:4543-52.
13. Mocellin S, Provenzano M, Rossi CR et al. DNA array-based gene profiling: From surgical specimen to the molecular portrait of cancer. Ann Surg 2005; 241:16-26.
14. Kallioniemi OP, Wagner U, Kononen J et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001; 10:657-62.
15. Le Naour F. Contribution of proteomics to tumor immunology. Proteomics 2001; 1:1295-1302.
16. Marincola FM, JafFee EM, Hicklin DJ et al. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273.
17. Toulouse A, Loubeau M, Morin J et al. RARbeta involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis. FASEB J 2000; 14:1224-32.
18. Mocellin S, Rossi CR, Nitti D. Cancer vaccine development: On the way to break immune tolerance to malignant cells. Exp Cell Res 2004; 299:267-78.
19. Garnett CT, Palena C, Chakraborty M et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004; 64:7985-94.
20. Renkvist N, Castelli C, Robbins PF et al. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50:3-15.
21. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-7.
22. Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264:716-9.
23. Maecker B, von B-B, Anderson KS et al. Linking genomics to immunotherapy by reverse immunology - 'immunomics' in the new millennium. Curr Mol Med 2001; 1:609-19.
24. Young AN, Amin MB, Moreno CS et al. Expression profiling of renal epithelial neoplasms: A method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001; 158:1639-51.
25. Takahashi M, Rhodes DR, Furge KA et al. Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification. Proc Natl Acad Sci USA 2001; 98:9754-9.
26. Boer JM, Huber WK, Sultmann H et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500- element cDNA array. Genome Res 2001; 11:1861-70.
27. Shi YY, Wang HC, Yin YH et al. Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br J Cancer 2005; 92:929-34.
28. Yoshitake Y, Nakatsura T, Monji M et al. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res 2004; 10:6437-48.
29. Mathiassen S, Lauemoller SL, Ruhwald M et al. Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity. Eur J Immunol 2001; 31:1239-46.
30. Wang T, Fan L, Watanabe Y et al. L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma. Oncogene 2001; 20:7699-709.
31. Weinschenk T, Gouttefangeas C, Schirle M et al. Integrated functional genomics approach for the design of patient- individual antitumor vaccines. Cancer Res 2002; 62:5818-27.
32. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811.
33. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001; 106:263-266.
34. Chen Z, Gordon JR, Zhang X et al. Analysis of the gene expression profiles of immature versus mature bone marrow-derived dendritic cells using DNA arrays. Biochem Biophys Res Commun 2002; 290:66-72.
35. Suciu-Foca Cortesini N, Piazza F, Ho E et al. Distinct mRNA microarray profiles of tolerogenic dendritic cells. Hum Immunol 2001; 62:1065-72.
36. Chen Z, Dehm S, Bonham K et al. DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy. Cell Immunol 2001; 214:60-71.
37. Figdor CG, De Vries IJ, Lesterhuis WJ et al. Dendritic cell immunotherapy: Mapping the way. Nat Med 2004; 10:475-80.
38. Ju XS, Hacker C, Madruga J et al. Towards determining the differentiation program of antigen-presenting dendritic cells by transcriptional profiling. Eur J Cell Biol 2003; 82:75-86.
39. Huang H, Li F, Gordon JR et al. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. Cancer Res 2002; 62:2043-51.
40. Zhang X, Chen Z, Huang H et al. DNA microarray analysis of the gene expression profiles of naive versus activated tumor-specific T cells. Life Sci 2002; 71:3005-17.
41. Carrabba MG, Castelli C, Maeurer MJ et al. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: Role of Melan-A/MART-1 optimized analogues. Cancer Res 2003; 63:1560-7.
42. Verdeil G, Puthier D, Nguyen C et al. Gene profiling approach to establish the molecular bases for partial versus full activation of naive CD8 T lymphocytes. Ann NY Acad Sci 2002; 975:68-76.
43. Keilholz U, Weber J, Finke JH et al. Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25:97-138.
44. Wang E, Marincola FM. A natural history of melanoma: Serial gene expression analysis. Immunol Today 2000; 21:619-23.
45. Wang E, Miller LD, Ohnmacht GA et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002; 62:3581-6.
46. Mocellin S, Panelli MC, Wang E et al. The dual role of IL-10. Trends Immunol 2003; 24:36-43.
47. Mocellin S, Panelli M, Wang E et al. IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun 2004; 5:621-30.
48. Kelly JM, Darcy PK, Markby JL et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 2002; 3:83-90.
49. Mocellin S, Rossi C, Nitti D et al. Dissecting tumor responsiveness to immunotherapy: The experience of peptide-based melanoma vaccines. Biochim Biophys Acta Rev Cancer 2003; 1653:61-71.
50. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-7.
51. Panelli MC, Wang E, Phan G et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002; 3:RESEARCH0035.